Amgen reports Q2 earnings decline
Amgen saw a 73% decline in net earnings in the second quarter of 2021, the company announced Aug. 3. Thousand Oaks-based Amgen, one of the world’s largest biotechnology companies, reported earnings per share of 81 cents for the quarter ended June 30, down from $3.05 per share in the same quarter last year. According to Read More →
With merger, ImmPact Bio plans growth and a move to LA
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
State vaccine rules could pave the way for private sector
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Our View: Vaccines are the way out of this COVID resurgence
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Opinion: How to turn the next crisis into something routine
By Angel Iscovich We are just emerging from a once-in-a-generation crisis. COVID-19 has disrupted not just nations, but the world. We can view events as Pre-Pandemic and Post-Pandemic. To say the coronavirus has also disrupted businesses would be the understatement of the year. Or decade. We have witnessed the destruction of companies and industries that Read More →
Opinion: When it comes to vaccines, trust the real experts
By Frank Kalman When it comes to facing a deadly disease, who you are relying on for advice truly matters! According to Dr. Philip Landrigan — epidemiologist and pediatrician and one of the world’s leading advocates of children’s health — children today live longer, healthier lives and suffer less disease than children at any previous Read More →
Amgen to buy biotech startup TeneoBio
Amgen announced July 27 that it plans to buy a privately held Bay Area biotech company called TeneoBio in an all-cash deal worth as much as $2.5 billion. The deal is expected to close in the second half of this year and calls for Amgen to pay $900 million up front for all outstanding shares Read More →
